Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...
SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the ...
M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...
Will Pharma Continue Efforts to Diversify Clinical Trials? The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ‘good ...
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy that affects women. PCOS is also a leading cause of infertility. Women with PCOS may present with obesity, amenorrhea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results